CHICAGO (GenomeWeb) – Multiple biomarkers are likely needed to more accurately predict patient response to anti-PD-1 immunotherapies, according to data presented at the American Society of Clinical Oncology meeting this week.
The theme was peppered throughout the meeting and especially emphasized at a clinical science symposium on Sunday, which touched on findings from several ongoing checkpoint blockade immunotherapy trials.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.